GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
Multiple Indian pharmaceutical companies including Zydus, Glenmark, Dr. Reddy's, and Alkem have launched semaglutide versions following patent expiry, dramatically reducing prices and expanding access. Companies are competing on both price and innovative delivery systems, with monthly therapy costs now ranging from Rs 1,300 to Rs 4,200. This development could significantly impact diabetes and obesity treatment in India, where over 100 million people live with diabetes.
The European Union has approved a higher 7.2 mg maintenance dose for Wegovy (semaglutide) for chronic weight management. Clinical trial data shows mean weight loss of 20-21% with the 7.2 mg dose compared to 17-18% with the standard 2.4 mg dose. The approval provides clinicians with an on-label option for patients with inadequate response to standard dosing.
Natco Pharma has received CDSCO approval to manufacture and market generic semaglutide injection in India, with a planned March 2026 launch. Eris Lifesciences will commercialize the product through a partnership.
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07002905 |
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities |
COMPLETED | PHASE2 |
| NCT06972992 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide |
COMPLETED | PHASE1 |
| NCT06703021 |
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity |
COMPLETED | PHASE2 |
| NCT06679959 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06671821 |
Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects |
COMPLETED | PHASE2 |
| NCT06427590 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects |
COMPLETED | PHASE1 |
| NCT01987427 |
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults |
COMPLETED | PHASE4 |
